Lp-PLA2-IN-3 manufacturers
- Lp-PLA2-IN-3
-
- $97.00
-
2026-07-14
- CAS:2196245-16-4
- Purity: 99.84%
- Supply Ability: 10g
- Lp-PLA2-IN-3
-
- $97.00
-
2026-07-14
- CAS:2196245-16-4
- Purity: 99.84%
- Supply Ability: 10g
|
| | Lp-PLA2-IN-3 Basic information |
| Product Name: | Lp-PLA2-IN-3 | | Synonyms: | Lp-PLA2-IN-3;LpPLA2IN3,Lp-PLA-2-IN-3,Lp PLA2 IN 3;Benzenesulfonamide, 4-amino-N-[4-[4-chloro-3-(trifluoromethyl)phenoxy]-3-cyanophenyl]-;Lp-PLA2-IN-3, 10 mM in DMSO | | CAS: | 2196245-16-4 | | MF: | C20H13ClF3N3O3S | | MW: | 467.85 | | EINECS: | | | Product Categories: | | | Mol File: | 2196245-16-4.mol |  |
| | Lp-PLA2-IN-3 Chemical Properties |
| Boiling point | 584.5±60.0 °C(Predicted) | | density | 1.57±0.1 g/cm3(Predicted) | | pka | 7.21±0.10(Predicted) | | form | Solid | | color | White to off-white |
| | Lp-PLA2-IN-3 Usage And Synthesis |
| Uses | Lp-PLA2-IN-3 is a potent and orally bioavailable lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor, with an IC50 of 14 nM for recombinant human Lp-PLA2 (rhLpPLA2)[1]. | | in vivo | Lp-PLA2-IN-3 (3 mg/kg; p.o.) treatment shows the Cmax, AUC0-24h, t1/2 and F were 0.27 μg/mL, 3.4 μg h/mL, 7.7 hours and 35.5%, respectively[1].
Lp-PLA2-IN-3 (1 mg/kg; i.v.) treatment shows the CL, Vss, and t1/2 were 3.1mL/min/kg, 0.3 L/kg, 4 hours, respectively[1]. | Animal Model: | Male SpragueDawley (SD) rats (180-220 g)[1] | | Dosage: | 3 mg/kg | | Administration: | p.o. (Pharmacokinetic Analysis) | | Result: | The Cmax, AUC0-24h, t1/2 and F were 0.27 μg/mL, 6.2 μg h/mL, 7.7 hours and 35.5%, respectively. |
| | References | [1] Liu Q, et al. Structure-Guided Discovery of Novel, Potent, and Orally Bioavailable Inhibitors of Lipoprotein-Associated Phospholipase A2. J Med Chem. 2017 Dec 28;60(24):10231-10244. DOI:10.1021/acs.jmedchem.7b01530 |
| | Lp-PLA2-IN-3 Preparation Products And Raw materials |
|